CoChat

The Effects of Olanzapine in Reducing the Emergence of Psychosis Among Nursing Home Patients With Alzheimer's Disease

Clark, W. Scott, Street, Jamie S., Feldman, Peter D., Breier, Alan · 2001 · The Journal of Clinical Psychiatry

The DOI matches its Crossref record.

Abstract

BACKGROUND: Elderly patients with Alzheimer's disease (AD) commonly exhibit psychotic symptoms, prompting clinicians to administer antipsychotics. This article compares the effects of olanzapine and placebo in the emergence of hallucinations or delusions in AD patients with symptoms of agitation/aggression but little or no psychotic symptomatology at baseline. METHOD: A multicenter, double-blind, placebo-controlled study was conducted in nursing home patients with AD according to DSM-IV criteria and symptoms of agitation/aggression and/or psychosis. Patients (N = 206) were randomly assigned to receive either placebo or fixed-dose olanzapine (5, 10, or 15 mg/day) for up to 6 weeks. This article analyzes data from a subgroup of patients (N = 165) with no or minimal delusions and/or hallucinations at baseline as measured by the Neuropsychiatric Inventory-Nursing Home Version (NPI/NH). Three subsets of patients were identified on the basis of their symptoms at baseline: those with no clinically significant hallucinations, those with no clinically significant delusions, and those with no clinically significant delusions or hallucinations. RESULTS: Of the patients without hallucinations or delusions at baseline (N = 75), the placebo-treated patients showed significantly greater development of these symptoms compared with olanzapine-treated patients overall (NPI/NH hallucinations + delusions mean change score, +2.73 vs. +0.27, p = .006). Similarly, of the patients without baseline hallucinations (N = 153), the placebo-treated patients showed greater hallucinations score increases than did olanzapine-treated patients overall (+1.25 vs. +0.33, p = .026), whereas patients without baseline delusions (N = 87) showed no significant treatment effects. Olanzapine had a favorable safety profile in each patient subset. CONCLUSION: These results suggest that, overall, olanzapine effectively attenuated emergence of psychosis in a short-term trial of patients with Alzheimer's disease.

Overview

Integrity signals

Registry

Crossref · 10.4088/jcp.v62n0108

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Still being checked.

Cited by

See all 101

Metadata

Authors
Clark, W. S., Street, J. S., Feldman, P. D., & Breier, A.
Affiliations
Eli Lilly (United States) (US)
Venue
The Journal of Clinical Psychiatry
Published
2001-01-15
Volume
62
Issue
1
Pages
34-40
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2095539522
Cited by
101
References
0
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2022: 3 · 2021: 4 · 2020: 1 · 2016: 1 · 2015: 2 · 2014: 2 · 2013: 2 · 2012: 5
FWCI
7.90
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
olanzapine, Alzheimer's disease, psychosis, hallucinations, delusions, nursing home residents, antipsychotic efficacy, agitation
MeSH terms
Olanzapine, Aged, Aged, 80 and over, Aggression, Alzheimer Disease, Benzodiazepines, Delusions, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Hallucinations, Humans, Male, Nursing Homes, Pirenzepine, Psychomotor Agitation, Psychotic Disorders, Antipsychotic Agents, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Effects of Olanzapine in Reducing the Emergence of Psychosis Among Nursing Home Patients With Alzheimer's Disease. https://app.cochat.ai/papers/10.4088/jcp.v62n0108
The paper
Clark, W. S., Street, J. S., Feldman, P. D., & Breier, A. (2001). The Effects of Olanzapine in Reducing the Emergence of Psychosis Among Nursing Home Patients With Alzheimer's Disease. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v62n0108

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.